Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. trimmed its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 7.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 3,533 shares of the biopharmaceutical company’s stock after selling 289 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Intra-Cellular Therapies were worth $300,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in ITCI. Wasatch Advisors LP lifted its position in shares of Intra-Cellular Therapies by 3.5% during the 3rd quarter. Wasatch Advisors LP now owns 3,848,588 shares of the biopharmaceutical company’s stock worth $281,601,000 after buying an additional 130,351 shares during the last quarter. Bellevue Group AG lifted its position in Intra-Cellular Therapies by 0.6% in the third quarter. Bellevue Group AG now owns 2,485,627 shares of the biopharmaceutical company’s stock valued at $181,873,000 after acquiring an additional 14,342 shares during the last quarter. State Street Corp boosted its stake in Intra-Cellular Therapies by 3.1% in the third quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company’s stock valued at $136,017,000 after acquiring an additional 56,664 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Intra-Cellular Therapies by 9.7% during the third quarter. Franklin Resources Inc. now owns 1,753,286 shares of the biopharmaceutical company’s stock worth $129,463,000 after purchasing an additional 155,655 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Intra-Cellular Therapies by 1.3% during the third quarter. Geode Capital Management LLC now owns 1,708,301 shares of the biopharmaceutical company’s stock worth $125,029,000 after purchasing an additional 22,128 shares in the last quarter. 92.33% of the stock is currently owned by hedge funds and other institutional investors.

Intra-Cellular Therapies Price Performance

Shares of NASDAQ:ITCI opened at $128.06 on Friday. The business has a 50-day moving average of $104.06 and a two-hundred day moving average of $87.27. The firm has a market capitalization of $13.62 billion, a PE ratio of -147.19 and a beta of 0.72. Intra-Cellular Therapies, Inc. has a 12 month low of $62.78 and a 12 month high of $128.15.

Wall Street Analyst Weigh In

ITCI has been the topic of a number of research reports. Needham & Company LLC restated a “hold” rating and set a $100.00 price target on shares of Intra-Cellular Therapies in a research note on Monday, January 13th. Canaccord Genuity Group lowered shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and raised their target price for the stock from $119.00 to $132.00 in a research report on Friday, January 31st. Piper Sandler reaffirmed a “neutral” rating and issued a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. StockNews.com assumed coverage on shares of Intra-Cellular Therapies in a research note on Saturday, February 8th. They set a “hold” rating for the company. Finally, JPMorgan Chase & Co. raised their price objective on shares of Intra-Cellular Therapies from $81.00 to $89.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. Nine investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $103.62.

Insider Buying and Selling at Intra-Cellular Therapies

In related news, CEO Sharon Mates sold 51,000 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total transaction of $4,375,800.00. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at approximately $91,834,228.20. This trade represents a 4.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.60% of the stock is currently owned by corporate insiders.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.